Novo Nordisk Shares Drop More Than 4% on Disappointing Obesity Pill Data
Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of monlunabant, an experimental drug it acquired as part of its $1 billion purchase of Canadian biotech company Inversago Pharmaceuticals last year.
2d
Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo ...
Novo Nordisk Global Business Services launches safe pharmaceuticals disposal initiative for employees: Our Bureau, Bengaluru Tuesday, September 17, 2024, 17:15 Hrs [IST] Novo Nord ...
The drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be ...
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Pioneer Group, a specialist in life science infrastructure and venture building, has teamed up with global healthcare company Novo Nordisk to launch a Golden Ticket designed to help accelerate ...
However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...
Axios on MSN1d
FTC sues drug middlemen for inflating insulin pricesThe Federal Trade Commission on Friday said it sued the three largest prescription drug middlemen, accusing them of illegally ...
Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback